Uterine leiomyosarcoma (LMS) is a rare uterine cancer that accounts for approximately 1% of all uterine cancers [1, 2] . However, because of its aggressive biology and resistance to chemotherapy, LMS causes approximately 70% of deaths caused by uterine malignant tumors [3, 4] . The symptoms and presenting characteristics of uterine LMS are almost indistinguishable from those of uterine leiomyoma [1] . Palpable mass and abnormal vaginal bleeding followed by weight loss and general weakness are the most common symptoms of uterine LMS [5, 6] . Intraoperatively, it is difficult to differentiate between LMS and leiomyoma based on visible evidence 
Introduction

Patients and treatment
The medical records of 50 patients with uterine LMS, who were diagnosed and treated at Samsung Medical Center from 2001 to 2017, were retrospectively reviewed. Per the routine protocol in patients with uterine LMS, patients underwent total hysterectomy and salpingo-oophorectomy (either bilateral or unilateral). The decision to perform adjuvant therapy (chemotherapy/radiation therapy) was made on the basis of the physician's opinion and patient's situation. To treat recurrent disease, chemotherapy, radiotherapy, and/or surgical resection of tumor were considered, if feasible. Available histological slides were also reviewed by a gynecologic pathologist. LMS was histologically defined by the presence of 2 of the following 3 criteria: 1) significant nuclear atypia, 2) >10 mitotic counts per 10 high-power field (HPF), and 3) coagulative tumor cell necrosis [11] . The modified 2009 International Federation of Gynecology and Obstetrics (FIGO) staging for LMS was used.
Clinicopathologic, surgical, and survival data were retrospectively gathered from electronic medical records. Prognostic variables that were included in this study were age at primary diagnosis, tumor suspected as leiomyoma with clinical characteristics before surgery, FIGO stage, residual disease status after primary surgery, tumor size, symptoms at diagnosis, grade, nuclear atypia, mitotic count (per 10 HPF), history of adjuvant therapy after primary surgery (chemotherapy/radiotherapy), recurrence pattern (peritoneal/hematogenous), and treatment after recurrence. Characteristics were assigned to categories for descriptive purposes and statistical analysis.
Tumor size was recorded on the basis of the maximum dimension of the tumor at pathologic analysis. The tumor grade, nuclear atypia, and mitotic count were recorded on the basis of final pathologic reports. Symptoms at diagnosis were limited to those related to the uterine mass at the time of diagnosis. Recurrence patterns were categorized into peritoneal and hematogenous metastases. Peritoneal recurrences were defined as the recurrence of metastatic lesions in the peritoneum of the pelvis and abdominal areas. Hematogenous recurrences were defined as visceral metastases such as those in the liver and lung parenchyma.
Recurrence-free survival (RFS) was defined as the time of initial diagnosis to the date of recurrence, death, or loss to follow-up. OS was described as the time between diagnosis and the patient's death or loss to follow-up. Survival after recurrence was described as the time between the diagnosis of recurrence and the patient's death or loss to follow-up. 
Statistical analysis
Results
The clinicopathologic characteristics of 50 patients with uterine LMS are presented in .0-29.0) cm, and moderate atypia was the most common feature (54.0%). Peritoneal recurrence was more common than hematogenous recurrence (66.7% vs. 33.3%) among patients with recurrence, and lymphatic recurrence was not observed in our data. Upon comparing characteristics between patients with and without recurrence, age, grade, mitotic count (10 HPF), and type of adjuvant therapy after primary surgery showed significant differences between the 2 groups (Table 1) . Univariate and multivariate analyses were performed to identify prognostic factors for RFS, OS, and survival after recurrence. In analysis for RFS (Table 2) , age, stage, tumor suspected as leiomyoma before surgery, residual status after primary surgery, tumor size, grade, nuclear atypia, mitotic count, and history of adjuvant chemotherapy/radiotherapy were significant variables in univariate analysis. Among these factors, age (hazard ratio [HR], 1.091; 95% CI, 1.045-1.140; P<0.001), residual disease (HR, 5.066; 95% CI, 1.880-13.651; P<0.001), mitotic count (>10/10 HPF, HR, 3.976; 95% CI, 1.420-11.131; P=0.009), and history of radiotherapy (HR, 0.209; 95% CI, 0.076-0.578; P=0.003) were significant variables in multivariate analysis. Fig. 1A and B show Kaplan-Meier curves for the time influenced by significant prognostic factors, residual disease status, and mitotic count. Significant prognostic factors for OS in univariate analysis were stage, residual disease after primary surgery, tumor size, grade, nuclear atypia, mitotic count, and adjuvant chemotherapy (Table 3) . In multivariate analysis, the presence of residual disease after primary surgery (HR, 3.740; 95% CI, 1.170-11.956; P=0.026) and severe nuclear atypia (HR, 6.041; 95% CI, 1.977-18.465; P=0.002) were significant prognostic factors associated with OS. Fig. 1C and D show survival curves influenced by residual disease status and nuclear atypia.
For analysis of survival after recurrence, only patients with recurrence were assessed (n=30). In univariate analysis, nuclear atypia was a significant factor (Table 4) . In multivariate analysis, the presence of residual disease status (HR, 11.304; 95% CI, 2.009-65.598; P=0.006), severe nuclear atypia (HR, 17.237; 95% CI, 2.902-102.384; P=0.002), and hematogenous recurrence (HR, 4.189; 95% CI, 1.032-17.000; P=0.045) were significantly associated with worse prognosis in survival after recurrence. The survival curve for survival after recurrence is shown in Fig. 1E and F.
Discussion
In our study, retrospective analysis of 50 patients with uterine LMS demonstrated possible prognostic factors for RFS, OS, and survival after recurrence. Age, residual disease status, mitotic count, and history of adjuvant radiotherapy were significant factors for RFS. Residual disease status and nuclear atypia were significant factors for OS, while residual disease status, nuclear atypia, and recurrence pattern were significant factors for survival after recurrence. Notably, complete resection of tumor at primary surgery was significantly associated with RFS, OS, and survival after recurrence.
A number of studies on the prognostic factors for uterine LMS have previously been published. The most important prognostic factor for survival in uterine LMS remains tumor stage at diagnosis. In 2009, FIGO presented a new classification for uterine LMS that includes tumor size, extrauterine involvement, and invasion to abdominal tissue [6] . In a previous study of Surveillance, Epidemiology, and End Results data of patients with uterine LMS from 2000 to 2012, almost half of patients were stage I, 14% were stage II and III, and 31% were stage IV [13] . Survival outcomes of uterine LMS are poor regardless of stage with 5-year disease-free survival of 65.7% in total the cohort [14] . In addition to FIGO stage, other reported prognostic factors include age, tumor size, [10, [15] [16] [17] [18] . Not all of these factors are included in current staging, yet they are related to prognosis. In a study analyzing prognostic factors using the National Cancer Database [19] , surgical resection remained the best effective management for uterine LMS. In the current study, stage-defining variables and other factors were used to analyze prognostic factors, and residual tumor status at primary surgery was also associated with RFS, OS, and survival after recurrence. With regard to surgical resection of uterine LMS, total hysterectomy with/without bilateral salpingooophorectomy is the standard treatment for patients with uterine-confined disease. Tumor removal should be en bloc, with an effort to avoid intraoperative rupture, morcellation, or spillage in the peritoneal cavity. Despite having metastatic disease, patients with both intraperitoneal and extraperitoneal disease are considered to be appropriate candidates for surgical resection due to limited systemic treatment options. In a previous retrospective study performed at the Memorial Sloan Kettering Cancer Center showed that optimal surgical resection was associated with improved progression-free survival [20] . Patients with hematogenous metastasis can also be considered as candidates for surgical resection. Several studies showed improved survival outcomes after pulmonary metastasectomy, and pulmonary metastasectomy is an effective option for selected patients with metastatic uterine LMS [21] [22] [23] [24] . According to previous studies, surgical resection for uterine LMS should be performed for better survival outcomes in the appropriate candidates. For uterine LMS, the effect of adjuvant therapy is still unclear due to its poor efficacy [25] . In our results, administration of adjuvant radiotherapy was associated with improved RFS. However, this was not significant in long-term survival, and survival advantage may not persist. Patients who un- 
